Buy Rating on Phio Pharmaceuticals: Early PH-762 Efficacy, Clean Safety Profile, and Solid Cash Runway Support Favorable Risk–Reward

Analyst Matthew Keller of H.C. Wainwright reiterated a Buy rating on Phio Pharmaceuticals, retaining the price target of $14.00.

Matthew Keller has given his Buy rating due to a combination of factors tied to PH-762’s emerging clinical profile and Phio Pharmaceuticals’ financial position. He highlights that the most recent Phase 1b data in cutaneous squamous cell carcinoma show a substantial proportion of patients achieving meaningful tumor clearance, including a notable number with complete responses. Keller also points to additional signs of activity in other skin cancers, such as Merkel cell carcinoma, reinforcing his view that PH-762 demonstrates a compelling anti-tumor effect at this early stage. Importantly, the absence of dose-limiting toxicities and the favorable tolerability across all dose cohorts support the drug’s therapeutic viability and potential for further dose optimization.

Keller further bases his Buy rating on the company’s cash position and operational runway, which he believes are sufficient to advance current clinical programs through key upcoming milestones. He expects additional updates in the coming months to clarify the development roadmap for PH-762 and the broader INTASYL platform, which could create further value inflection points. In his view, the combination of promising Phase 1b efficacy, a clean safety profile to date, and a balance sheet that can support continued execution justifies a favorable risk–reward outlook on the stock.

According to TipRanks, Keller is an analyst with an average return of -30.0% and a 18.60% success rate. Keller covers the Healthcare sector, focusing on stocks such as Gyre Therapeutics, InflaRx, and Galectin Therapeutics.